3 Drugs Stocks Dragging The Industry Down

TheStreet highlights 3 stocks pushing the health services industry lower today.
By TheStreet Wire ,

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 4 points (0.0%) at 18,344 as of Wednesday, July 13, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,211 issues advancing vs. 1,725 declining with 124 unchanged.

The Drugs industry currently sits down 1.5% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the industry include

ACADIA Pharmaceuticals

(

ACAD

), down 4.6%,

Illumina

(

ILMN

), down 2.4%,

Incyte

(

INCY

), down 1.7%,

Vertex Pharmaceuticals

(

VRTX

), down 1.1% and

Sanofi

(

SNY

), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Abbott Laboratories

(

ABT

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Abbott Laboratories is down $0.28 (-0.7%) to $41.93 on light volume. Thus far, 3.6 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 10.9 million shares. The stock has ranged in price between $41.89-$42.52 after having opened the day at $42.25 as compared to the previous trading day's close of $42.21.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abbott Laboratories manufactures and sells health care products worldwide. Abbott Laboratories has a market cap of $61.5 billion and is part of the health care sector. Shares are down 5.4% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Abbott Laboratories

as a

hold

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full

Abbott Laboratories Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Amgen

(

AMGN

) is down $0.88 (-0.5%) to $161.08 on average volume. Thus far, 1.2 million shares of Amgen exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $160.31-$162.66 after having opened the day at $162.50 as compared to the previous trading day's close of $161.96.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amgen Inc., a biotechnology company, engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. Amgen has a market cap of $121.0 billion and is part of the health care sector. Shares are down 0.2% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Amgen a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates

Amgen

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Amgen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Shire

(

SHPG

) is down $1.98 (-1.0%) to $193.33 on light volume. Thus far, 751,179 shares of Shire exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $192.81-$195.91 after having opened the day at $195.46 as compared to the previous trading day's close of $195.31.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Shire plc, a biotech company, together with its subsidiaries, engages in the research, development, licensing, manufacture, marketing, distribution, and sale of medicines for patients with rare diseases and other select conditions. Shire has a market cap of $37.1 billion and is part of the health care sector. Shares are down 4.7% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Shire a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Shire

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Shire Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...